There are a number of other ongoing translational projects and we welcome industry/academic collaborations to accelerate this process. These include a collaborative protocol for a placebo-controlled double-blind Phase II virtual trial with a pilot & feasibility phase to assess the efficacy and safety of cannabidiol (CBD) for the treatment of home self-isolating health care worker patients with mild COVID-19 .
Up to 50% of all cancer patients experience pain, and as many as 90% with advanced cancer live with chronic debilitating pain that can be difﬁcult to treat. The pain contributes signiﬁcantly to increased morbidity and reduced quality of life, characteri s ed by fatigue, depression, insomnia, and weight loss. The evaluation and development of cannabinoid compounds may lead to novel therapies which provide better pain relief and improve the quality of life in patients with chronic pain conditions.
We aim to test the efficacy and potency of a range of novel cannabinoid related compounds, including those that target receptors such as the cannabinoid receptors CB1 and CB2, and to develop new analgesic treatments for use in the clinic. These novel agents are evaluated using in vitro models of hypersensitivity in cultured neurons from rodent and human sensory ganglia. We have recently shown that Cannabidiol (CBD) at low doses , corresponding to plasma concentrations observed physiologically , inhibits or desensitizes neuronal TRPV1 signalling by inhibiting the adenylyl cyclase – cAMP pathway, which is essential for maintaining TRPV1 phosphorylation and sensitization. CBD also facilitated calcineurin-mediated TRPV1 inhibition. These mechanisms may underlie nociceptor desensitization , and the therapeutic effect of CBD in animal models and patients with acute and chronic pain.
Cannabis-based medicines were rescheduled under UK law in 2018 allowing doctors to prescribe these treatments to patients for a wide range of conditions. We are interested in the evaluation and development of novel cannabinoid therapies targeting two main areas: 1) inflammation & cancer, with a current focus on pancreatic ductal adenocarcinoma (PDAC) and 2) acute/ post- surg ical, neuropathic and cancer -related pain .
There is an increasing unmet clinical need for several types of pain treatment. Many c urrent pharmacological treatments have limited efficacy and significant side-effects. Chronic neuropathic pain represents a great need – between 4 and 12 patients are treated before a single patient reports 50% pain relief, and clinical trials in chemotherapy-induced painful neuropathy have been disappointing. Advances in the non-opioid treatment of acute and chronic pain, such as with novel cannabinoids, are therefore urgently needed.
Inflammation & Cancer
Cannabinoids have shown merits in not only alleviating the unwanted side – effects of cancer treatments but have also displayed promising pre-clinical antitumour properties, through modulating processes which include apoptosis and autophagy. Co-administration of cannabinoids with cytotoxic therapies may enhance the potency of these outcomes . In cancers that are refractory to systemic therapy, t hese synergistic effects warrant further investigation to select combinations for clinical translation and evaluation .
Inflammation and Cancer
THC is a psychoactive substance that can create a ‘high’ feeling. It can affect how your brain works, changing your mood and how you feel.
Cannabis has been used medicinally and recreationally for hundreds of years.
CBD oil, cannabis oil and hemp oil
There are trials looking at whether Sativex can help with cancer pain that has not responded to other painkillers.
We need more research to know if cannabis or the chemicals in it can treat cancer.
Industrial hemp production itself does not seem viable in the UK unless it can find a way to compete with international producers. However, there is an incredible support for UK farmers to be legally able to process hemp material and then feed these extractions into the CBD supply.
Let’s look at the projections. The CMC admitted that this information was difficult to track down. They needed to commission an independent market insight and research agency to find the details shared below.
These regular users are happy to spend significant amounts of money on cannabidiol treatment. Their subjective experience leads them to believe that CBD has a beneficial value. All of the CBD users in the UK deserve regulations that can assure purity while not constricting product expression, availability, or quality.
These results indicate that a majority of these products do not deliver an experience consistent with product labeling. None of the issues appearing here are threatening to human health, but some of them do cross into gray market areas. One truth stands out when looking at these results. Purity can be significantly improved in the pursuit of the highest quality.
The results indicate that there are high-quality cannabidiol products on the market, but some others have issues such as low potency and contaminants. Most choices are imperfect but passable for consumers.
When classifying CBD products, it can be challenging to understand what type of regulations are needed. CBD can be seen as a medicinal, a cosmetic, or food. No claims should be made, although on-going studies can be discussed impartially. You must have a product license on an ingredient to address these potential properties, but this is impossible with the current legal CBD status, where it is not classified as food or medicine.
Having open dialogues between consumers, distributors, and government agencies will help this process happen smoothly. Educational resources need to be made available for citizens and politicians. Ethical regulatory rules need to put into place to eliminate lousy practices and to facilitate quality product creation.